DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yu, Byeongjun | ko |
dc.contributor.author | Hwang, Dobeen | ko |
dc.contributor.author | Jeon, Hyungsu | ko |
dc.contributor.author | Kim, Hyungjun | ko |
dc.contributor.author | Lee, Yonghyun | ko |
dc.contributor.author | Keum, Hyeongseop | ko |
dc.contributor.author | Kim, Jinjoo | ko |
dc.contributor.author | Lee, Dong Yun | ko |
dc.contributor.author | Kim, Yujin | ko |
dc.contributor.author | Chung, Junho | ko |
dc.contributor.author | Jon, Sangyong | ko |
dc.date.accessioned | 2019-03-19T01:25:24Z | - |
dc.date.available | 2019-03-19T01:25:24Z | - |
dc.date.created | 2019-03-04 | - |
dc.date.created | 2019-03-04 | - |
dc.date.issued | 2019-02 | - |
dc.identifier.citation | ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, v.58, no.7, pp.2005 - 2010 | - |
dc.identifier.issn | 1433-7851 | - |
dc.identifier.uri | http://hdl.handle.net/10203/251624 | - |
dc.description.abstract | Peptide-based therapeutics have suffered from a short plasma half-life. On the other hand, antibodies suffer from poor penetration into solid tumors owing to their large size. Herein, we present a new molecular form, namely a hybrid complex between a hapten-labeled bispecific peptide and an anti-hapten antibody (HyPEP-body), that may be able to overcome the aforementioned limitation. The bispecific peptide containing a cotinine tag was synthesized by linking a peptide specific to fibronectin extra domainB (EDB) and a peptide able to bind and inhibit vascular endothelial growth factor (VEGF), yielding cot-biPEP(EDB-VEGF). Simple mixing of cot-biPEP(EDB-VEGF) and anti-cotinine antibody (Ab(cot)) yielded the hybrid complex, HyPEP(EDB-VEGF). HyPEP(EDB-VEGF) retained the characteristics of the included peptides, and showed improved pharmacokinetic behavior. Moreover, HyPEP(EDB-VEGF) showed tumor growth inhibition with excellent tumor accumulation and penetration. These findings suggest that the hybrid platform described here offers a solution for most peptide therapeutics that suffer from a short circulation half-life in blood. | - |
dc.language | English | - |
dc.publisher | WILEY-V C H VERLAG GMBH | - |
dc.title | A Hybrid Platform Based on a Bispecific Peptide-Antibody Complex for Targeted Cancer Therapy | - |
dc.type | Article | - |
dc.identifier.wosid | 000458828000021 | - |
dc.identifier.scopusid | 2-s2.0-85060649920 | - |
dc.type.rims | ART | - |
dc.citation.volume | 58 | - |
dc.citation.issue | 7 | - |
dc.citation.beginningpage | 2005 | - |
dc.citation.endingpage | 2010 | - |
dc.citation.publicationname | ANGEWANDTE CHEMIE-INTERNATIONAL EDITION | - |
dc.identifier.doi | 10.1002/anie.201811509 | - |
dc.contributor.localauthor | Jon, Sangyong | - |
dc.contributor.nonIdAuthor | Hwang, Dobeen | - |
dc.contributor.nonIdAuthor | Kim, Hyungjun | - |
dc.contributor.nonIdAuthor | Lee, Yonghyun | - |
dc.contributor.nonIdAuthor | Lee, Dong Yun | - |
dc.contributor.nonIdAuthor | Chung, Junho | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | antibodies | - |
dc.subject.keywordAuthor | aptides | - |
dc.subject.keywordAuthor | cancer therapy | - |
dc.subject.keywordAuthor | fibronectin | - |
dc.subject.keywordAuthor | peptide therapeutics | - |
dc.subject.keywordPlus | ENDOTHELIAL GROWTH-FACTOR | - |
dc.subject.keywordPlus | ED-B | - |
dc.subject.keywordPlus | FIBRONECTIN ISOFORM | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | RADIOIMMUNOTHERAPY | - |
dc.subject.keywordPlus | ANGIOGENESIS | - |
dc.subject.keywordPlus | I-131-L19SIP | - |
dc.subject.keywordPlus | BEVACIZUMAB | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordPlus | MIGRATION | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.